Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies

Author： Eyzaguirre Alexandra  

Publisher： Springer Publishing Company

ISSN： 1776-2596

Source： Targeted Oncology, Vol.3, Iss.4, 2008-10, pp. : 235-243

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical development of EGFR-tyrosine kinase inhibitors in Japan

By Nakagawa Kazuhiko  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 1, 2006-11 ,pp. : 33-37

Springer Publishing Company

Access to resources Recommend Favorite

Clinical development of EGFR-tyrosine kinase inhibitors in Japan

By Nakagawa Kazuhiko  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 7, 2006-11 ,pp. : 33-37

Springer Publishing Company

Access to resources Recommend Favorite

Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

By  

Oncology Reports, Vol. 33, Iss. 1, 2015-01 ,pp. : 391-396

Spandidos Publications

Access to resources Recommend Favorite

Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors

By  

Oncology Reports, Vol. 33, Iss. 3, 2015-01 ,pp. : 1499-1504

Spandidos Publications

Access to resources Recommend Favorite

HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme

By Raizer Jeffrey  

Journal of Neuro-Oncology, Vol. 74, Iss. 1, 2005-08 ,pp. : 77-86

Springer Publishing Company

Access to resources Recommend Favorite